NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Down 96.0% in October

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) was the target of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 17,900 shares, a decrease of 96.0% from the September 30th total of 451,700 shares. Based on an average daily volume of 2,610,000 shares, the days-to-cover ratio is presently 0.0 days.

NovaBay Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN:NBY traded down $0.01 during midday trading on Friday, reaching $0.55. The company’s stock had a trading volume of 56,177 shares, compared to its average volume of 952,608. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $12.84. The firm has a market cap of $2.32 million, a PE ratio of -0.06 and a beta of 2.82.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 146.20% and a negative net margin of 79.70%. The company had revenue of $2.40 million during the quarter. On average, analysts anticipate that NovaBay Pharmaceuticals will post -2.54 EPS for the current fiscal year.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.